Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The Association Between Timely Opioid Administration and Hospitalization in Children With Sickle Cell Disease Presenting to the Emergency Department in Acute Pain
source: Pediatric Blood & Cancer
year: 2020
authors: Cagla S. Muslu, Matthew Kopetsky, Mark Nimmer, Alexis Visotcky, Raphael Fraser, David C. Brousseau
summary/abstract:Objective:
To evaluate the association between timely ED opioid administration and hospitalization rates in children with SCD.
Methods:
Retrospective cohort of children presenting to a children’s hospital ED with SCD pain between January 1, 2014, and April 30, 2018. Visits were extracted using ICD codes, chief complaints, and receipt of at least one opioid, and then reviewed to confirm the visit was an uncomplicated pain crisis. The primary outcome was hospitalization, yes or no. Generalized estimating equations were used to determine adjusted odds of hospitalization for the timely administration of initial and second doses of opioids.
Results:
Of the 902 eligible visits, 368 (40.8%) resulted in hospitalization. The mean (SD) age was 11.9 (± 5.2) years. The first opioid was administered within 60 minutes of arrival in 601 (66.6%) visits. The second opioid was administered within 30 minutes of the first in 84 (12.3%) visits. Receipt of the first opioid within 60 minutes of arrival was not associated with decreased hospitalization (1.30 [0.96‐1.76]). However, receipt of the second dose within 30 minutes of the first was associated with decreased hospitalization (0.56 [0.33‐0.94]).
Conclusion:
This study suggests an association between children with SCD receiving a second dose within 30 minutes of the first opioid dose and decreased hospitalizations.
DOI: 10.1002/pbc.28268
read more
+myBinderRelated Content
-
Assessing the safety and efficacy of converting adults with sickle cell disease from full agonist opioids to bupreno...Background: The management of pain in ad...
-
Quality of care in sickle cell disease: Cross-sectional study and development of a measure for adults reporting on a...Documented deficiencies in adult sickle ...
-
Sickle cell advocate wins fight for high-dose opioidsGeorge H. Carter appears to have won h...
-
CMO Speaks: Making ED Care Better for SCD – Progress in 2023Welcome to CMO Speaks, a blog featuring ...
-
Vitamin D Supplements May Reduce Pain-related Emergency Room Visits in Children With SCDTaking vitamin D supplements may lower t...
-
Methadone provides pain relief for kids with sickle cellMany children with sickle cell disease e...
-
APS Scientific Meeting 2019The American Pain Society will hold its ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.